Manufacturer:
AbbVie
Route of Administration:
Oral
Site of Care:
Outpatient
Website:
Approved Indication:
- treatment of adults and pediatric patients 3 years of age and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis
- treatment of adult and pediatric patients 3 years of age and older with HCV genotype 1 infection who previously have been treated with a regimen containing an HCV NS5A or an NS3/4A protease inhibitor, but not both
Conditions:
- Chronic Viral Hepatitis C
Therapeutic Area:
- Gastroenterology
- Hepatology
- Infectious Disease